Literature DB >> 15601303

Malignancy in pheochromocytomas.

Kaisa Salmenkivi1, Päivi Heikkilä, Caj Haglund, Johanna Arola.   

Abstract

A catecholamine-secreting tumor arising from the chromaffin cells of the sympathoadrenal system was first termed pheochromocytoma by Poll in 1905. The term refers to the dysky (pheo) color (chromo) of the cut surface of the tumor when exposed to dichromate. Pheochromocytomas most commonly arise from the adrenal medulla. Extraadrenally located pheochromocytomas are called paragangliomas, and arise from the paraganglion system. An adrenal pheochromocytoma is usually a rounded, gray-white, firm tumor 3 to 5 cm in diameter. When larger, they can adhere to adjacent structures, although still not metastasizing. Most pheochromocytomas are benign. However, approximately 10% of these tumors metastasize. It is almost impossible to differentiate a benign from a malignant tumor only by histological criteria. Classically only metastasized tumors are considered malignant for certain. Many attempts have been made to find markers that would predict the future behavior of an unmetastasized pheochromocytoma. In this overview of malignancy in pheochromocytomas, different steps of the tumorigenesis and several markers associated with them are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15601303     DOI: 10.1111/j.1600-0463.2004.apm1120901.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  7 in total

1.  Clinical significance of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma.

Authors:  Azusa Nakazawa; Tetsuya Higuchi; Noboru Oriuchi; Yukiko Arisaka; Keigo Endo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

Review 2.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

Review 3.  [Pheochromocytoma - still a challenge].

Authors:  N Reisch; M K Walz; Z Erlic; H P H Neumann
Journal:  Internist (Berl)       Date:  2009-01       Impact factor: 0.743

4.  A two-decade experience of head and neck paragangliomas in a whole population-based single centre cohort.

Authors:  T Anttila; V Häyry; T Nicoli; J Hagström; K Aittomäki; P Vikatmaa; M Niemelä; K Saarilahti; A Mäkitie; L J Bäck
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-29       Impact factor: 2.503

5.  Clinicopathological analysis of paraganglioma with literature review.

Authors:  Ning Feng; Wen-Yan Zhang; Xiao-Ting Wu
Journal:  World J Gastroenterol       Date:  2009-06-28       Impact factor: 5.742

6.  Exploring Nitric Oxide (NO)-Releasing Celecoxib Derivatives as Modulators of Radioresponse in Pheochromocytoma Cells.

Authors:  Florian Brandt; Martin Ullrich; Verena Seifert; Cathleen Haase-Kohn; Susan Richter; Torsten Kniess; Jens Pietzsch; Markus Laube
Journal:  Molecules       Date:  2022-10-05       Impact factor: 4.927

7.  Strain-specific metastatic phenotypes in pheochromocytoma allograft mice

Authors:  Martin Ullrich; Josephine Liers; Mirko Peitzsch; Anja Feldmann; Ralf Bergmann; Ulrich Sommer; Susan Richter; Stefan R Bornstein; Michael Bachmann; Graeme Eisenhofer; Christian G Ziegler; Jens Pietzsch
Journal:  Endocr Relat Cancer       Date:  2018-10-05       Impact factor: 5.678

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.